NCT03724253View on ClinicalTrials.gov

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

June 20, 2019

Study Completion Date

July 5, 2019

Conditions
Breast CancerProstate CancerColorectal CancerNon Small Cell Lung CancerSmall Cell Lung Cancer
Interventions
DRUG

[68Ga]-NeoBOMB1

\[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors

Trial Locations (3)

Unknown

Medical University Innsbruck Department of Nuclear Medicine, Innsbruck

University of Grenoble - Hopital Michallon, Service de Medicine Nucleaire, La Tronche

University of Bordeaux, Unite TEP RECHERCHE - Hopital Xavier Arnozan, Pessac

Sponsors
All Listed Sponsors
lead

Advanced Accelerator Applications

INDUSTRY